CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:
Our subsidiary, Creative Medical Technologies, Inc. ("CMT"), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction ("ED"), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing "re-programmed" stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0K | $11.0K | $9.0K | $88.6K | $87.8K | $164.5K | $165.5K | $124.4K | $4.8K | $0 |
| Cost of revenue | $2.2K | $4.4K | $3.6K | $28.5K | $47.9K | $50.6K | $45.5K | $70.4K | $8.0K | $0 |
| Gross profit | $3.8K | $6.6K | $5.4K | $60.1K | $39.8K | $113.9K | $120.0K | $54.0K | -$3.2K | $0 |
| R&D | $2.3M | $2.4M | $2.0M | $6.3M | $109.2K | $0 | $0 | $96.6K | $260.1K | $85.3K |
| SG&A | $3.8M | $3.2M | $3.6M | $3.9M | $3.0M | $1.2M | $1.2M | $1.1M | $898.5K | $665.0K |
| Total operating expenses | $6.1M | $5.8M | $5.6M | $10.3M | $3.2M | $1.2M | $1.3M | $1.2M | $1.2M | $759.7K |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M | -$3.1M | -$1.1M | -$1.1M | -$1.1M | -$1.2M | -$759.7K |
| Interest expense | — | — | — | $0 | $4.3M | $1.2M | $1.9M | $1.4M | $377.6K | $6.4K |
| Pre-tax income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M | -$36.3M | -$8.5M | -$13.7M | -$2.7M | -$766.1K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M | -$36.3M | -$8.5M | -$13.7M | -$2.7M | -$766.1K |
| EPS, basic | — | — | — | -0.93 | 7.37 | -62.69 | — | — | — | — |
| EPS, diluted | -2.52 | -3.71 | -3.76 | -0.93 | 5.61 | -62.69 | -0.82 | -3.50 | -0.03 | -0.01 |
| Shares, diluted (wtd. avg.) | $2.4M | $1.5M | $1.4M | $10.9M | $3.2M | $579.5K | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.2M | $5.9M | $3.5M | $8.3M | $10.7M | $98.0K | $88.6K | $304.1K | $13.7K | $221.9K |
| Receivables | — | — | — | $0 | $2.5K | $0 | $5.6K | $9.6K | $4.8K | $0 |
| Inventory | $0 | $2.2K | $6.6K | $10.2K | $10.9K | $0 | — | — | — | — |
| Total current assets | $7.4M | $6.1M | $10.3M | $18.7M | $10.7M | $98.0K | $94.2K | $313.7K | $18.5K | $221.9K |
| Other intangibles | $407.2K | $530.6K | $441.0K | $435.6K | $527.7K | $619.8K | $436.6K | $163.5K | $184.6K | $100.6K |
| Total assets | $7.8M | $6.7M | $10.7M | $19.2M | $11.3M | $717.8K | $530.8K | $477.2K | $203.1K | $322.5K |
| Accounts payable | $270.7K | $273.5K | $317.3K | $3.3M | $761.9K | $350.9K | $320.8K | $331.8K | $237.6K | $66.4K |
| Total current liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M | $40.5M | $8.6M | $4.5M | $2.4M | $453.9K |
| Long-term debt | — | — | — | — | — | — | — | — | $493.2K | — |
| Total liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M | $40.5M | $8.6M | $4.5M | $2.4M | $480.3K |
| Retained earnings | -$70.6M | -$64.6M | -$59.1M | -$53.8M | -$43.7M | -$61.9M | -$25.6M | -$17.1M | -$3.4M | -$766.6K |
| Total equity | $7.5M | $6.3M | $10.3M | $15.9M | $10.2M | -$39.8M | -$8.1M | -$4.0M | -$2.2M | -$157.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M | -$2.2M | -$434.6K | -$1.2M | -$1.1M | -$889.6K | -$445.2K |
| Stock-based compensation | $3.5K | $36.6K | $36.6K | $68.7K | $595.4K | $170.3K | $0 | $1.9K | $144.2K | $2.6K |
| Investing cash flow | -$50.5K | $6.3M | $3.4M | -$10.1M | $0 | -$250.0K | $0 | — | $0 | -$10.0K |
| Financing cash flow | $7.2M | $1.5M | -$271.0K | $15.5M | $12.8M | $693.9K | $997.7K | $1.3M | $681.5K | $677.0K |
| Buybacks | $10.0K | $175.0K | $271.0K | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002534.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |